Top 5 venture capital deals of H1 2009

With 2009 half over, we're stopping to take a look back at the venture capital deals closed in the first part of the year. The fundraising market was looking quite bleak as 2009 got underway; many biotechs had already gone under as they waited for cash that would never come. But as always, strong science and good management rose to the top, and many promising drug developers were able to scare up significant rounds of funding.

Take a look at the biotech and pharma companies that rose to the top of the investment heap over the last six months.

Clovis Oncology $145M
Hyperion Therapeutics $60M
Cempra Pharmaceuticals $46M
Victory Pharma $45M
Aileron Therapeutics



Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”